News articles about ProNAi Therapeutics (NASDAQ:SRRA) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ProNAi Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.7463523652174 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
A number of brokerages recently weighed in on SRRA. ValuEngine raised shares of ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research raised shares of ProNAi Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Jefferies Group LLC reaffirmed a “hold” rating on shares of ProNAi Therapeutics in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. ProNAi Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $3.25.
Shares of ProNAi Therapeutics (NASDAQ:SRRA) traded up 1.65% on Tuesday, reaching $1.59. 83,618 shares of the company were exchanged. ProNAi Therapeutics has a 52-week low of $1.31 and a 52-week high of $2.01. The stock has a 50 day moving average of $1.55 and a 200-day moving average of $1.54. The company’s market capitalization is $83.11 million.
This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-pronai-therapeutics-srra-stock-price/1654500.html
ProNAi Therapeutics (NASDAQ:SRRA) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. On average, analysts predict that ProNAi Therapeutics will post ($0.91) EPS for the current fiscal year.
About ProNAi Therapeutics
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.